Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
1313453
Reference Type
Journal Article
Title
Minocycline attenuates the development of diabetic neuropathic pain: possible anti-inflammatory and anti-oxidant mechanisms
Author(s)
Pabreja, K; Dua, K; Sharma, S; Padi, SS; Kulkarni, SK
Year
2011
Is Peer Reviewed?
1
Journal
European Journal of Pharmacology
ISSN:
0014-2999
EISSN:
1879-0712
Publisher
Elsevier
Volume
661
Issue
1-3
Page Numbers
15-21
Language
English
PMID
21536024
DOI
10.1016/j.ejphar.2011.04.014
Web of Science Id
WOS:000291372600003
URL
https://linkinghub.elsevier.com/retrieve/pii/S0014299911004043
Exit
Abstract
Painful neuropathy, a common complication of diabetes mellitus is characterized by allodynia and hyperalgesia. Recent studies emphasized on the role of non-neuronal cells, particularly microglia in the development of neuronal hypersensitivity. The purpose of the present study is to evaluate the effect of minocyline, a selective inhibitor of microglial activation to define the role of neuroimmune activation in experimental diabetic neuropathy. Cold allodynia and thermal and chemical hyperalgesia were assessed and the markers of inflammation and oxidative and nitrosative stress were estimated in streptozotocin-induced diabetic rats. Chronic administration of minocycline (40 and 80 mg/kg, i.p.) for 2 weeks started 2 weeks after diabetes induction attenuated the development of diabetic neuropathy as compared to diabetic control animals. In addition, minocyline treatment reduced the levels of interleukin-1β and tumor necrosis factor-α, lipid peroxidation, nitrite and also improved antioxidant defense in spinal cords of diabetic rats as compared to diabetic control animals. In contrast, minocycline (80 mg/kg, per se) had no effect on any of these behavioral and biochemical parameters assessed in age-matched control animals. The results of the present study strongly suggest that activated microglia are involved in the development of experimental diabetic neuropathy and minocycline exerted its effect probably by inhibition of neuroimmune activation of microglia. In addition, the beneficial effects of minocycline are partly mediated by its anti-inflammatory effect by reducing the levels of proinflammatory cytokines and in part by modulating oxidative and nitrosative stress in the spinal cord that might be involved in attenuating the development of behavioral hypersensitivity in diabetic rats.
Tags
IRIS
•
Formaldehyde
Immune Section
Exclude - miscellaneous reasons
Retroactive RIS import
2013
HERO Formaldehyde Immune Section 20Mar2013
2014
Immune_HERO_allyr
•
Nitrate/Nitrite
Supplemental LitSearch Update 1900-2015
PubMed
WoS
New to project
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity